2011 Scrip 100: Pharma can breathe easy over China's tort law, for now
This article was originally published in Scrip
Companies operating in China are coming to grips with the potential impact of the country's first comprehensive tort liability legislation, including its provisions on product recalls and punitive damages. How worried should they be, asks Eugene Chen.
You may also be interested in...
In the face of robust pharmaceutical market growth, an increase in adverse drug reactions and higher consumer demands, is China's drugs industry facing a perfect storm, asks Eugene Chen.